SNAT2 isexpressed in the brain but also in other tissues and it is overexpressedin several cancer types,25,29,63,64 and therefore, predicting itsrole in the pharmacokinetics of LAT1-utilizing compounds is challenging.When comparing the findings of the present study to the pharmacokineticstudies and accumulation of these prodrugs into the brain that havebeen reported previously (Table 1), no clear correlation on how these additional mechanismscould affect was found [Kp values (AUCbrain/AUCplasma) were on the same level; 0.017–0.082,the only exception was compound 6; 0.317]. The gene discussed is SLC38A2; the disease is cancer.